Diksha Nagpal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Diksha Nagpal has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Deepak Kaushik
Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak 124001, Haryana, India
4 shared publications - Himanshu Kathuria
Nusmetics Pte Ltd., E-Centre@Redhill, Singapore 139471, Singapore
3 shared publications - Shakti Nagpal
Department of Pharmacy and Pharmaceutical Sciences, National University of Singapore, Singapore 117544, Singapore
3 shared publications - Murali Monohar Pandey
Department of Pharmacy, Birla Institute of Technology and Science, Vidya Vihar Campus, Pilani 333031, Rajasthan, India
2 shared publications - Vineet Mittal
Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak 124001, Haryana, India
2 shared publications Philippe Jeandet
1 shared publication
Latest Publications
- Open Access
Engineering Next-Generation Taxane Nanomedicines for Clinical Translation
Background: Taxanes have been a cornerstone in the management of a wide range of cancers, including ovarian, breast, and lung cancer, owing to their microtubule-stabilizing mechanism. Despite their clinical success, their therapeutic utility remains constrained by poor aqueous solubility, a need for toxic solubilizing vehicles, unpredictable pharmacokinetics, and systemic toxicity. Nanomedicine has redefined chemotherapeutic delivery paradigms, with liposomal systems emerging as leading platforms due to their safety and scalability. Purpose: This review aims to critically evaluate the physicochemical and formulation barriers that have limited the successful development of taxane-loaded nanoformulations and to highlight how model-informed principles can be leveraged to improve drug retention, stability, and translational potential. Review Scope: Early liposomal systems faced challenges, including premature drug release and rapid carrier opsonization, limitations that are particularly relevant for compounds with unfavorable biopharmaceutical properties. For taxanes such as paclitaxel, strong partitioning into the lipid bilayer can result in membrane destabilization and premature leakage. Conventional passive loading approaches have shown limited success for these molecules, prompting exploration of active loading strategies. Remote loading utilizes transmembrane gradients to improve drug retention and loading efficiency by concentrating therapeutics within the liposomal core; however, the non-ionizable nature of taxanes restricts the applicability of this approach. Conclusions: These limitations highlight the need for a rational nanocarrier design focused on drug–lipid interactions, physicochemical optimization, surface engineering, controlled release, manufacturing feasibility, and regulatory considerations. Integrating these principles may facilitate the development of robust, scalable, and clinically relevant taxane liposomal formulations, supporting the effective translation of these natural-product-derived therapeutics into improved cancer treatment strategies.
Open AccessEngineering Next-Generation Taxane Nanomedicines for Clinical Translation
Background: Taxanes have been a cornerstone in the management of a wide range of cancers, including ovarian, breast, and lung cancer, owing to their microtubule-stabilizing mechanism. Despite their clinical success, their therapeutic utility remains constrained by poor aqueous solubility, a need for toxic solubilizing vehicles, unpredictable pharmacokinetics, and systemic toxicity. Nanomedicine has redefined chemotherapeutic delivery paradigms, with liposomal systems emerging as leading platforms due to their safety and scalability. Purpose: This review aims to critically evaluate the physicochemical and formulation barriers that have limited the successful development of taxane-loaded nanoformulations and to highlight how model-informed principles can be leveraged to improve drug retention, stability, and translational potential. Review Scope: Early liposomal systems faced challenges, including premature drug release and rapid carrier opsonization, limitations that are particularly relevant for compounds with unfavorable biopharmaceutical properties. For taxanes such as paclitaxel, strong partitioning into the lipid bilayer can result in membrane destabilization and premature leakage. Conventional passive loading approaches have shown limited success for these molecules, prompting exploration of active loading strategies. Remote loading utilizes transmembrane gradients to improve drug retention and loading efficiency by concentrating therapeutics within the liposomal core; however, the non-ionizable nature of taxanes restricts the applicability of this approach. Conclusions: These limitations highlight the need for a rational nanocarrier design focused on drug–lipid interactions, physicochemical optimization, surface engineering, controlled release, manufacturing feasibility, and regulatory considerations. Integrating these principles may facilitate the development of robust, scalable, and clinically relevant taxane liposomal formulations, supporting the effective translation of these natural-product-derived therapeutics into improved cancer treatment strategies.
- Open Access
- 2 September 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (9) , 1078
Management and Prevention of Neurodegenerative Disorders: Can Antioxidant-Rich Dietary Interventions Help?
Neurodegenerative diseases are associated with the senescence of functional neurons, which hampers brain functions. These diseases are caused by the accumulation of reactive oxygen species, reactive nitrogen species, cholinesterase malfunction, neuronal inflammation, and mitochondrial dysfunction. The incidence of neurodegenerative disease has been on the rise. Current therapeutic interventions are expensive, exhibit poor efficacy, and have numerous side effects. Several studies have explored the potential of crucial dietary substances rich in antioxidants and micronutrients in alleviating the clinical manifestations of such deadly diseases. Consumption of sufficient antioxidants, fatty acids, and polyphenols in regular diets delays the onset of neurodegenerative diseases. Several medicinal plants, such as Withania somnifera, Curcuma longa, Panax ginseng, Ginkgo biloba, aloe vera, Punica granatum, and various phytoextracts, contain such micronutrients in reasonable amounts. Specific dietary interventions, supplements, and patterns such as the Mediterranean-DASH intervention for neurodegenerative delay, ketogenic, paleolithic, and Wahls elimination diets have been beneficial in neurodegenerative conditions. These diet interventions and other functional foods can be an attractive, non-invasive, and inexpensive approach in the management and prevention of neurodegenerative conditions. This review discusses potential pharmacological bases involved in neurodegeneration, covering mitochondrial damage, impaired mitophagy, neuroinflammation, ferroptosis, glymphatic clearance dysfunction, brain–body interactions, and disruption of vagus nerve stimulation. The review further highlights clinical diet interventions and assorted functional foods, including fruits, vegetables, vitamins, specific supplements, and special diets, for neurodegenerative conditions. The discussion extends insights into clinical research and trials of these functional foods under neurodegenerative conditions. Overall, dietary interventions show promise in the prevention and management of neurodegenerative conditions.
- 2 September 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (9) , 1078
Open AccessManagement and Prevention of Neurodegenerative Disorders: Can Antioxidant-Rich Dietary Interventions Help?
Neurodegenerative diseases are associated with the senescence of functional neurons, which hampers brain functions. These diseases are caused by the accumulation of reactive oxygen species, reactive nitrogen species, cholinesterase malfunction, neuronal inflammation, and mitochondrial dysfunction. The incidence of neurodegenerative disease has been on the rise. Current therapeutic interventions are expensive, exhibit poor efficacy, and have numerous side effects. Several studies have explored the potential of crucial dietary substances rich in antioxidants and micronutrients in alleviating the clinical manifestations of such deadly diseases. Consumption of sufficient antioxidants, fatty acids, and polyphenols in regular diets delays the onset of neurodegenerative diseases. Several medicinal plants, such as Withania somnifera, Curcuma longa, Panax ginseng, Ginkgo biloba, aloe vera, Punica granatum, and various phytoextracts, contain such micronutrients in reasonable amounts. Specific dietary interventions, supplements, and patterns such as the Mediterranean-DASH intervention for neurodegenerative delay, ketogenic, paleolithic, and Wahls elimination diets have been beneficial in neurodegenerative conditions. These diet interventions and other functional foods can be an attractive, non-invasive, and inexpensive approach in the management and prevention of neurodegenerative conditions. This review discusses potential pharmacological bases involved in neurodegeneration, covering mitochondrial damage, impaired mitophagy, neuroinflammation, ferroptosis, glymphatic clearance dysfunction, brain–body interactions, and disruption of vagus nerve stimulation. The review further highlights clinical diet interventions and assorted functional foods, including fruits, vegetables, vitamins, specific supplements, and special diets, for neurodegenerative conditions. The discussion extends insights into clinical research and trials of these functional foods under neurodegenerative conditions. Overall, dietary interventions show promise in the prevention and management of neurodegenerative conditions.
- 7 October 2023
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 89
Targeted therapies against breast cancer: Clinical perspectives, obstacles and new opportunities
- 7 October 2023
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 89
Targeted therapies against breast cancer: Clinical perspectives, obstacles and new opportunities
- 5 September 2022
- Published by Springer Nature in Environmental Science and Pollution Research
- Vol. 29 (47) , 1-36
Current clinical status of new COVID-19 vaccines and immunotherapy
COVID-19, caused by SARS-CoV-2, is a positive-strand RNA belonging to Coronaviridae family, along with MERS and SARS. Since its first report in 2019 in Wuhan, China, it has affected over 530 million people and led to 6.3 million deaths worldwide until June 2022. Despite eleven vaccines being used worldwide already, new variants are of concern. Therefore, the governing bodies are re-evaluating the strategies for achieving universal vaccination. Initially, the WHO expected that vaccines showing around 50–80% efficacy would develop in 1–2 years. However, US-FDA announced emergency approval of the two m-RNA vaccines within 11 months of vaccine development, which enabled early vaccination for healthcare workers in many countries. Later, in January 2021, 63 vaccine candidates were under human clinical trials and 172 under preclinical development. Currently, the number of such clinical studies is still increasing. In this review, we have summarized the updates on the clinical status of the COVID-19 and the available treatments. Additionally, COVID-19 had created negative impacts on world’s economy; affected agriculture, industries, and tourism service sectors; and majorly affected low-income countries. The review discusses the clinical outcomes, latest statistics, socio-economic impacts of pandemic and treatment approaches against SARS-CoV-2, and strategies against the new variant of concern. The review will help understand the current status of vaccines and other therapies while also providing insights about upcoming vaccines and therapies for COVID-19 management. Graphical abstract
- 5 September 2022
- Published by Springer Nature in Environmental Science and Pollution Research
- Vol. 29 (47) , 1-36
Current clinical status of new COVID-19 vaccines and immunotherapy
COVID-19, caused by SARS-CoV-2, is a positive-strand RNA belonging to Coronaviridae family, along with MERS and SARS. Since its first report in 2019 in Wuhan, China, it has affected over 530 million people and led to 6.3 million deaths worldwide until June 2022. Despite eleven vaccines being used worldwide already, new variants are of concern. Therefore, the governing bodies are re-evaluating the strategies for achieving universal vaccination. Initially, the WHO expected that vaccines showing around 50–80% efficacy would develop in 1–2 years. However, US-FDA announced emergency approval of the two m-RNA vaccines within 11 months of vaccine development, which enabled early vaccination for healthcare workers in many countries. Later, in January 2021, 63 vaccine candidates were under human clinical trials and 172 under preclinical development. Currently, the number of such clinical studies is still increasing. In this review, we have summarized the updates on the clinical status of the COVID-19 and the available treatments. Additionally, COVID-19 had created negative impacts on world’s economy; affected agriculture, industries, and tourism service sectors; and majorly affected low-income countries. The review discusses the clinical outcomes, latest statistics, socio-economic impacts of pandemic and treatment approaches against SARS-CoV-2, and strategies against the new variant of concern. The review will help understand the current status of vaccines and other therapies while also providing insights about upcoming vaccines and therapies for COVID-19 management. Graphical abstract